SCHEMBL1106646

SCHEMBL1106646

CC(C)(C)[Si](C)(C)O[C@@H]1C(n2c(Br)nc3c(N)ncnc32)OC2CO[P@@](=O)(Nc3ccccc3)O[C@H]21

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 14/20 0.51
PDE4B Q07343 14/20 0.51
PDE4C Q08493 14/20 0.51
PDE4D Q08499 14/20 0.51
RAPGEF3 O95398 2/20 0.51
TSHR P16473 1/20 0.51
HIF1A Q16665 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
PMP22 Q01453 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
STING1 Q86WV6 1/20 0.40
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1106647 1.00 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL14030518 1.00 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL1133069 1.00 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL13320175 0.90 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL1106648 0.89 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL1137740 0.89 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL15906304 0.86 RAPGEF3 (0.42) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL1106668 0.86 RAPGEF3 (0.42) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL10098848 0.86 RAPGEF3 (0.42) PDE4APDE4BPDE4CPDE4DRAPGEF3
SCHEMBL1106644 0.85 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DRAPGEF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765844-B1 PURINE NUCLEOTIDE DERIVATIVES SOLVELL AS (NO) 2014-07-30 EP disclosed
US-8153609-B2 Purine nucleotide derivatives LAURAS AS (NO) 2012-04-10 US disclosed
US-20080293665-A1 Purine Nucleotide Derivatives LAURAS AS (NO) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293665-A1 Purine Nucleotide Derivatives CGAS, PDE8A, PDE7A PDE4A 9/4885PDE4B 11/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.